GREECE

Decision-Making

Decision-making Stakeholders: The Ministry of Health (MoH), Ministry of Finance (MoF), the National Vaccination Committee (NITAG), the National Organization for Public Health (EODY), Scientific Societies, Pharmacies

Introducing a new vaccine: The National Immunization Committee assesses new vaccines and updates the national vaccination schedule. The Health Technology Assessment Committee conducts scientific assessments of new vaccine products, and the Negotiation Committee conducts price negotiations. The MoH oversees the process and decides on vaccine inclusion and reimbursement.

Ministry of Finance Involvement: Yes. The MoF collaborates closely with the MoH to determine the vaccine budget.

Financing

Primary Funding Source: Government funding through a joint ministerial decision by the MoF and MoH to define the annual vaccine budget.

Financial Mechanisms for Sustainability: A separate vaccine budget has been established to provide financial stability.

Ringfencing: Yes. A designated budget for vaccines is incorporated into the national budget.

Critical Financing Challenges: Demographic changes, increasing health needs and adjusting the vaccine budget to the government priorities.

	Yes	No
Ministry of Finance Involvement	/	
Ringfencing	/	
External Funding Sources		/
Influence of Public-Private Partnerships		/

Landscape

History: Following economic crises, Greece implemented several reforms affecting pharmaceutical spending, including vaccines, with significant price controls and budget constraints. Currently, there is political will to include new technology/vaccines in the NIP and increase vaccine coverage rates.

Most funded campaigns: COVID-19 and seasonal influenza; the pharmaceutical industry typically finances other campaigns.

Future: Greece aims to maintain a separate vaccine budget post-COVID, with ongoing financing through European Commission purchasing agreements for COVID-19 vaccines.



Centralised
Health System







8.6% of GDP spent

of healthcare budget is spent on prevention

Over-65 influenza vaccination coverage (2021)

Adult vaccination (18+) recommendation against 16 diseases:

COVID-19 Diphtheria Tetanus Pertussis



Poliomyelitis

Haemophilus influenzae

type B infection Hepatitis B

Pneumococcal disease Meningococcal disease

Measles

Mumps Rubella

Varicella

Influenza Herpes Zoster

Hepatitis A

